Table 3.
Lipid Parameters at Baseline and Post Three Months in Patients who Switched TDF/FTC to ABC/3TC.
| Median (IQR) n=18 | ||||||
|---|---|---|---|---|---|---|
| Baseline | Post three months | p values | ||||
| LDL, mg/dL | 92 | ( 82 , 105) | 114 | ( 97 , 137) | < 0.001 | |
| HDL, mg/dL | 43 | ( 36 , 49) | 48 | ( 41 , 54) | 0.001 | |
| TG, mg/dL | 166 | ( 100 , 212) | 142 | ( 111 , 177) | 0.948 | |
| TC, mg/dLα | 159 | ( 143 , 178) | 184 | ( 174 , 218) | 0.009 | |
p values for comparison between blood concentrations of lipid parameters at baseline and those of at post three months are determined by Wilcoxon signed-rank tests. Baseline is defined as the first day when ABC/3TC.was prescribed. Abbreviations: IQR: interquartile range, TDF: tenofovir, FTC: emtricitabine, ABC: abacavir, 3TC: lamivdine, α TC n=12